vs
ITT INC.（ITT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ITT INC.的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 12.5%，领先0.2%），ITT INC.同比增速更快（13.5% vs 5.9%），ITT INC.自由现金流更多（$187.4M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 7.6%）
ITT Inc是一家总部位于美国康涅狄格州斯坦福德的制造企业，前身为ITT集团，主要面向航空航天、交通、能源及工业领域供应特种零部件，旗下设有工业流程、运动技术、连接与控制技术三大业务板块。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ITT vs RVTY — 直观对比
营收规模更大
ITT
是对方的1.4倍
$772.1M
营收增速更快
ITT
高出7.6%
5.9%
净利率更高
RVTY
高出0.2%
12.5%
自由现金流更多
ITT
多$25.6M
$161.8M
两年增速更快
RVTY
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $131.7M | $98.4M |
| 毛利率 | 35.5% | — |
| 营业利润率 | 17.0% | 14.5% |
| 净利率 | 12.5% | 12.7% |
| 营收同比 | 13.5% | 5.9% |
| 净利润同比 | 3.7% | 3.9% |
| 每股收益（稀释后） | $1.64 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ITTRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $999.1M | $698.9M | ||
| Q2 25 | $972.4M | $720.3M | ||
| Q1 25 | $913.0M | $664.8M | ||
| Q4 24 | $929.0M | $729.4M | ||
| Q3 24 | $885.2M | $684.0M | ||
| Q2 24 | $905.9M | $691.7M | ||
| Q1 24 | $910.6M | $649.9M |
净利润ITTRVTY
| Q4 25 | $131.7M | $98.4M | ||
| Q3 25 | $126.9M | $46.7M | ||
| Q2 25 | $121.0M | $53.9M | ||
| Q1 25 | $108.4M | $42.2M | ||
| Q4 24 | $127.0M | $94.6M | ||
| Q3 24 | $161.1M | $94.4M | ||
| Q2 24 | $119.2M | $55.4M | ||
| Q1 24 | $111.0M | $26.0M |
毛利率ITTRVTY
| Q4 25 | 35.5% | — | ||
| Q3 25 | 35.6% | 53.6% | ||
| Q2 25 | 35.7% | 54.5% | ||
| Q1 25 | 34.6% | 56.5% | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 35.5% | 56.3% | ||
| Q2 24 | 34.9% | 55.7% | ||
| Q1 24 | 33.0% | 54.6% |
营业利润率ITTRVTY
| Q4 25 | 17.0% | 14.5% | ||
| Q3 25 | 18.0% | 11.7% | ||
| Q2 25 | 18.0% | 12.6% | ||
| Q1 25 | 16.5% | 10.9% | ||
| Q4 24 | 17.2% | 16.3% | ||
| Q3 24 | 23.5% | 14.3% | ||
| Q2 24 | 17.6% | 12.4% | ||
| Q1 24 | 16.4% | 6.8% |
净利率ITTRVTY
| Q4 25 | 12.5% | 12.7% | ||
| Q3 25 | 12.7% | 6.7% | ||
| Q2 25 | 12.4% | 7.5% | ||
| Q1 25 | 11.9% | 6.4% | ||
| Q4 24 | 13.7% | 13.0% | ||
| Q3 24 | 18.2% | 13.8% | ||
| Q2 24 | 13.2% | 8.0% | ||
| Q1 24 | 12.2% | 4.0% |
每股收益（稀释后）ITTRVTY
| Q4 25 | $1.64 | $0.86 | ||
| Q3 25 | $1.62 | $0.40 | ||
| Q2 25 | $1.52 | $0.46 | ||
| Q1 25 | $1.33 | $0.35 | ||
| Q4 24 | $1.54 | $0.77 | ||
| Q3 24 | $1.96 | $0.77 | ||
| Q2 24 | $1.45 | $0.45 | ||
| Q1 24 | $1.35 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $919.9M |
| 总债务越低越好 | $521.5M | — |
| 股东权益账面价值 | $4.1B | $7.3B |
| 总资产 | $6.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.13× | — |
8季度趋势，按日历期对齐
现金及短期投资ITTRVTY
| Q4 25 | $1.7B | $919.9M | ||
| Q3 25 | $516.4M | $931.4M | ||
| Q2 25 | $467.9M | $991.8M | ||
| Q1 25 | $439.8M | $1.1B | ||
| Q4 24 | $439.3M | $1.2B | ||
| Q3 24 | $460.9M | $1.2B | ||
| Q2 24 | $425.5M | $2.0B | ||
| Q1 24 | $423.0M | $1.7B |
总债务ITTRVTY
| Q4 25 | $521.5M | — | ||
| Q3 25 | $577.7M | — | ||
| Q2 25 | $622.5M | — | ||
| Q1 25 | $4.5M | — | ||
| Q4 24 | $232.6M | — | ||
| Q3 24 | $467.8M | — | ||
| Q2 24 | $190.0M | — | ||
| Q1 24 | $230.5M | — |
股东权益ITTRVTY
| Q4 25 | $4.1B | $7.3B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.8B | $7.6B | ||
| Q4 24 | $2.8B | $7.7B | ||
| Q3 24 | $2.7B | $7.9B | ||
| Q2 24 | $2.6B | $7.9B | ||
| Q1 24 | $2.6B | $7.8B |
总资产ITTRVTY
| Q4 25 | $6.3B | $12.2B | ||
| Q3 25 | $5.1B | $12.1B | ||
| Q2 25 | $5.0B | $12.4B | ||
| Q1 25 | $4.8B | $12.4B | ||
| Q4 24 | $4.7B | $12.4B | ||
| Q3 24 | $4.9B | $12.8B | ||
| Q2 24 | $4.4B | $13.4B | ||
| Q1 24 | $4.4B | $13.4B |
负债/权益比ITTRVTY
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.09× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $227.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $187.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 17.8% | 21.0% |
| 资本支出强度资本支出/营收 | 3.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.73× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $547.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ITTRVTY
| Q4 25 | $227.8M | $182.0M | ||
| Q3 25 | $173.9M | $138.5M | ||
| Q2 25 | $153.7M | $134.3M | ||
| Q1 25 | $113.4M | $128.2M | ||
| Q4 24 | $223.2M | $174.2M | ||
| Q3 24 | $123.9M | $147.9M | ||
| Q2 24 | $157.7M | $158.6M | ||
| Q1 24 | $57.8M | $147.6M |
自由现金流ITTRVTY
| Q4 25 | $187.4M | $161.8M | ||
| Q3 25 | $146.2M | $120.0M | ||
| Q2 25 | $137.3M | $115.5M | ||
| Q1 25 | $76.6M | $112.2M | ||
| Q4 24 | $186.8M | $149.8M | ||
| Q3 24 | $87.3M | $125.6M | ||
| Q2 24 | $134.5M | $136.6M | ||
| Q1 24 | $30.1M | $129.7M |
自由现金流率ITTRVTY
| Q4 25 | 17.8% | 21.0% | ||
| Q3 25 | 14.6% | 17.2% | ||
| Q2 25 | 14.1% | 16.0% | ||
| Q1 25 | 8.4% | 16.9% | ||
| Q4 24 | 20.1% | 20.5% | ||
| Q3 24 | 9.9% | 18.4% | ||
| Q2 24 | 14.8% | 19.7% | ||
| Q1 24 | 3.3% | 20.0% |
资本支出强度ITTRVTY
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 3.9% | 3.4% | ||
| Q3 24 | 4.1% | 3.3% | ||
| Q2 24 | 2.6% | 3.2% | ||
| Q1 24 | 3.0% | 2.7% |
现金转化率ITTRVTY
| Q4 25 | 1.73× | 1.85× | ||
| Q3 25 | 1.37× | 2.97× | ||
| Q2 25 | 1.27× | 2.49× | ||
| Q1 25 | 1.05× | 3.03× | ||
| Q4 24 | 1.76× | 1.84× | ||
| Q3 24 | 0.77× | 1.57× | ||
| Q2 24 | 1.32× | 2.87× | ||
| Q1 24 | 0.52× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ITT
| Industrial Process | $423.1M | 40% |
| Motion Technologies | $360.8M | 34% |
| Connect Control Technologies | $271.2M | 26% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
